Exploring potential neuroimaging biomarkers for the response to non-steroidal anti-inflammatory drugs in episodic migraine

Table 3 Subgroup analysis results

Variables	Count	Percent (%)	OR (95% CI)	p value	p for interaction
Overall	118	100.00	0.19 (0.09 ~ 0.41)	< 0.001
Age					0.087
≤ 33 years	60	50.80	0.09 (0.03 ~ 0.29)	< 0.001
> 33 years	58	49.20	0.38 (0.13 ~ 1.08)	0.073
Sex					0.231
Male	20	16.90	0.05 (0.02 ~ 0.41)	0.016
Female	98	83.10	0.23 (0.10 ~ 0.54)	0.001
Education					0.903
≤ 12 years	60	50.80	0.18 (0.06 ~ 0.53)	0.003
> 12 years	58	49.20	0.20 (0.06 ~ 0.59)	0.005
Migraine duration					0.159
≤ 8 years	64	54.20	0.11 (0.03 ~ 0.33)	< 0.001
> 8 years	54	45.80	0.35 (0.11 ~ 1.02)	0.060
VAS					0.839
≤ 6 score	64	54.20	0.17 (0.06 ~ 0.50)	0.002
> 6 score	54	45.80	0.21 (0.06 ~ 0.64)	0.008
Frequency					0.217
≤ 3 days/month	59	50.00	0.11 (0.03 ~ 0.34)	< 0.001
> 3 days/month	59	50.00	0.30 (0.10 ~ 0.88)	0.032
Attack duration					0.126
≤ 12 h	63	53.40	0.33 (0.11 ~ 0.90)	0.033
> 12 h	55	46.60	0.09 (0.02 ~ 0.30)	< 0.001
MIDAS					0.416
≤ 20 score	59	50.00	0.13 (0.04 ~ 0.41)	0.001
> 20 score	59	50.00	0.26 (0.08 ~ 0.75)	0.015
HIT-6					0.871
≤ 62 score	61	51.70	0.20 (0.06 ~ 0.58)	0.004
> 62 score	57	48.30	0.18 (0.05 ~ 0.53)	0.003
GAD-7					0.496
≤ 5 score	60	50.80	0.25 (0.08 ~ 0.71)	0.011
> 5 score	58	49.20	0.14 (0.04 ~ 0.44)	0.001
PHQ-9					0.228
≤ 7 score	69	58.50	0.28 (0.10 ~ 0.75)	0.013
> 7 score	49	41.50	0.10 (0.03 ~ 0.36)	0.001
PSQI					0.847
≤ 7 score	37	31.40	0.17 (0.03 ~ 0.66)	0.015
> 7 score	81	68.60	0.20 (0.07 ~ 0.49)	0.001

GAD-7 Generalized Anxiety Disorder 7-Item, HIT-6 Headache Impact Test 6-Item, MIDAS Migraine Disability Assessment Scale, PHQ-9 Patient Health Questionnaire 9-Item, PSQI Pittsburgh Sleep Quality Index, VAS Visual Analogue Scale

ISSN: 1129-2377